What one share of Pulmonx holds
We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”).
Pulmonx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.10 |
|---|---|
| Profit | −$1.15 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.74 |
| Cash and investments | $1.30 |
| Debt | $0.87 |
| Book value | $0.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $11.94 | −$11.03 | $0.19 | −$11.17 | — | −$99.91 |
| 2019 | $18.35 | −$11.66 | $0.41 | −$12.10 | — | −$89.22 |
| 2020 | $3.21 | −$3.16 | $0.09 | −$3.10 | — | — |
| 2021 | $1.34 | −$1.35 | $0.10 | −$1.25 | — | $5.23 |
| 2022 | $1.45 | −$1.59 | $0.04 | −$1.25 | — | $4.10 |
| 2023 | $1.81 | −$1.60 | $0.02 | −$1.01 | — | $3.07 |
| 2024 | $2.14 | −$1.44 | $0.04 | −$0.84 | — | $2.16 |
| 2025 | $2.22 | −$1.33 | $0.01 | −$0.81 | — | $1.30 |
Common questions about Pulmonx
How much does one share of Pulmonx earn?
Over the last 12 months, Pulmonx lost $1.15 for each share on $2.10 of sales.
Does Pulmonx pay a dividend?
Pulmonx didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Pulmonx’s book value per share?
Pulmonx’s book value is $0.91 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Pulmonx have?
Each share of Pulmonx has $1.30 of cash and investments and $0.87 of debt, as of June 30, 2026.
What is Pulmonx’s free cash flow per share?
−$0.74 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Pulmonx bought back shares?
Pulmonx’s share count rose about 2329% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.